<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679080</url>
  </required_header>
  <id_info>
    <org_study_id>TreatOI</org_study_id>
    <nct_id>NCT01679080</nct_id>
  </id_info>
  <brief_title>The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta</brief_title>
  <official_title>The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are
      fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o. The aim of the
      present study is to investigate the effect of treatment of adult OI patients with
      bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass, fracture
      risk and quality of life.

      The investigators will therefore conduct a double blind, placebo controlled trial, taking
      genotype and previous antiresorptive therapy into account.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>Three years</time_frame>
    <description>Dual-energy X-ray absorptiometry scans are performed at the lumbar spine, hip and whole body twice yearly. The value of the lumbar BMD is the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fracture risk</measure>
    <time_frame>Three years</time_frame>
    <description>Participants are asked to report fractures throughout the study. Medical examination yearly with a focus on possible new fractures. Columnar x-ray before and after the study investigate new fractures.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Zolendronic acid, 3 yr + placebo teriparatide, 2 yr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>yearly intravenous infusion of 5mg active zoledronic acid in 3 yr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide 2 yr; active zol in 3rd yr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No active treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Observation in three years, no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>antiresorptive and calcium and vitamin D</description>
    <arm_group_label>Zolendronic acid, 3 yr + placebo teriparatide, 2 yr</arm_group_label>
    <arm_group_label>teriparatide 2 yr; active zol in 3rd yr</arm_group_label>
    <other_name>zolendronate</other_name>
    <other_name>Aclasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>anabolic and calcium and vitamin D</description>
    <arm_group_label>teriparatide 2 yr; active zol in 3rd yr</arm_group_label>
    <other_name>PTH</other_name>
    <other_name>Forsteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No active treatment</intervention_name>
    <description>Calcium and vitamin D</description>
    <arm_group_label>No active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of osteogenesis imperfecta

          -  BMD&lt;-1.0 or

        Exclusion Criteria:

          -  creatinine clearance &lt;30mL/min

          -  treatment with glucocorticoids &gt; 5mg daily during the last 3 months

          -  metabolic bone disease or vitamin d deficiency

          -  liver or kidney disease

          -  contradictions to zoledronic acid or teriparatide

          -  increased baseline risk of osteosarcoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente Langdahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bente Langdahl</last_name>
    <phone>0045 7846 7678</phone>
    <email>bente.langdahl@aarhus.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jannie Hald</last_name>
    <phone>0045 7846 7681</phone>
    <email>janniehald@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Osteoporosis clinic; department of endocrinology and metabolism</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jannie Hald</last_name>
      <phone>0045 7846 7686</phone>
      <email>janniehald@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jannie Hald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of endocrinology</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens-Erik B Jensen</last_name>
      <email>Jens-Erik.Beck.Jensen@hvh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jens-Erik B Jensen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology M</name>
      <address>
        <city>Odense</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Folkestad</last_name>
      <email>lfolkestad@health.sdu.dk</email>
    </contact>
    <investigator>
      <last_name>Lars Folkestad</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

